FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Andrew Evens

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Andrew M Evens; Fangxin Hong
How can outcomes be improved for older patients with Hodgkin lymphoma?
Andrew M Evens; Richard I Fisher; Randy D Gascoyne; Leo I Gordon; Mary Gospodarowicz; Fangxin Hong; Richard T Hoppe; Ranjana Advani; Nancy L Bartlett; Bruce D Cheson; Joseph M Connors; Brad S Kahl; Thomas P Miller; Patrick J Stiff; Henry Wagner; Sandra J Horning
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.
Rupali Roy; Stewart Spies; Daina Variakojis; Jeffrey Cilley; Andrew M Evens; Lillia Gallot; Leo I Gordon; Annette Larson; David Patton; Alfred Rademaker; Jane N Winter
Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Andrew Evens (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Andrew M Evens; Fangxin Hong
How can outcomes be improved for older patients with Hodgkin lymphoma?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(12):1502-5.
2013: Andrew M Evens; Richard I Fisher; Randy D Gascoyne; Leo I Gordon; Mary Gospodarowicz; Fangxin Hong; Richard T Hoppe; Ranjana Advani; Nancy L Bartlett; Bruce D Cheson; Joseph M Connors; Brad S Kahl; Thomas P Miller; Patrick J Stiff; Henry Wagner; Sandra J Horning
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.
British journal of haematology 2013;161(1):76-86.
2013: Rupali Roy; Stewart Spies; Daina Variakojis; Jeffrey Cilley; Andrew M Evens; Lillia Gallot; Leo I Gordon; Annette Larson; David Patton; Alfred Rademaker; Jane N Winter
Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.
Leukemia & lymphoma 2013;54(3):497-502.
2013: M Agulnik; Bruce E Brockstein; Andrew M Evens; Borko D Jovanovic; S H Okuno; M von Mehren; J L Yarber; R S Benjamin
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24(1):257-63.
2012: Beverly P Nelson; Anjen Chenn; Andrew M Evens; John Maddalozzo; Kristy L Wolniak; Maria Proytcheva
Early posttransplant lymphoproliferative disease: clinicopathologic features and correlation with mTOR signaling pathway activation.
American journal of clinical pathology 2012;138(4):568-78.
2012: Andrew M Evens; M Antillón; B Aschebrook-Kilfoy; B C-H Chiu
Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(8):2128-37.
2012: Jeffrey J Raizer; Laurie Rice; Margaret Schwartz; Claudia Tellez; James P Chandler; Andrew M Evens; Christopher C Getch; Alfred Rademaker; Sean A Grimm
Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma.
Cancer 2012;118(15):3743-8.
2012: Deepa Jagadeesh; Bruce A Woda; Jacqueline Draper; Andrew M Evens
Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.
Current treatment options in oncology 2012;13(1):122-36.
2012: Andrew M Evens; Leo I Gordon; Stephanie Gregory; Britt Hanson; Irene B Helenowski; Borko Jovanovic; Reem Karmali; Annette Larsen; June M McKoy; Chadi Nabhan; Benjamin Parsons; Erika Ramsdale; Scott Smith; Sonali M Smith
A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era.
Blood 2012;119(3):692-5.
2012: Chadi Nabhan; Benjamin Parsons; Erika Ramsdale; Scott Smith; Sonali M Smith; Josephine Feliciano; Stephanie Gregory; Britt Hanson; Andrew Hantel; Irene B Helenowski; Reem Karmali; Annette Larsen; June McKoy; Andrew M Evens
Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome.
British journal of haematology 2012;156(2):196-204.
2011: Savita Bhalla; Bojie Dai; Andrew M Evens; Leo I Gordon; Sheila Prachand; Ronald B Gartenhaus
The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma.
Blood 2011;118(4):1052-61.
2011: Andrew M Evens; Borko D Jovanovic; Y-C Su; Dennis W Raisch; D Ganger; Steven M. Belknap; M-S Dai; Brian Chiu; B Fintel; Y Cheng; S-S Chuang; Michael Y Lee; T-Y Chen; S-F Lin; C-Y Kuo
Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(5):1170-80.
2011: Allison Goddard; Judy H Borovicka; Dennis P West; Andrew M Evens; Anne Laumann
Diffuse large B-cell lymphoma associated with the use of biologic and other investigational agents: the importance of long-term post-marketing safety surveillance.
Journal of drugs in dermatology : JDD 2011;10(1):80-3.
2010: Andrew M Evens; Rupali Roy; Danielle Sterrenberg; Michelle Z Moll; Amy Chadburn; Leo I Gordon
Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.
Current oncology reports 2010;12(6):383-94.
2010: Shuo Yang; Andrew M Evens; Sheila Prachand; Amareshwar T K Singh; Savita Bhalla; Kevin David; Leo I Gordon
Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculata.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(19):4755-68.
2010: Andrew M Evens
Improving outcomes in PTLD.
Oncology (Williston Park, N.Y.) 2010;24(10):944, 946-7.
2010: Savita Bhalla; Leo I Gordon; Kevin David; Sheila Prachand; Amareshwar T K Singh; Shuo Yang; Jane N Winter; Dongsheng Guo; Thomas O'Halloran; Leonidas C Platanias; Andrew M Evens
Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms.
British journal of haematology 2010;150(3):365-9.
2010: Amareshwar T K Singh; Andrew M Evens; Reilly J Anderson; Jennifer A Beckstead; Natesan Sankar; Antonella Sassano; Savita Bhalla; Shuo Yang; Leonidas C Platanias; Trudy M Forte; Robert O Ryan; Leo I Gordon
All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma.
British journal of haematology 2010;150(2):158-69.
2010: Sairah Ahmed; Jane N Winter; Leo I Gordon; Andrew M Evens
Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications.
Leukemia & lymphoma 2010;51(7):1163-77.
2010: Amareshwar T K Singh; Andrew M Evens; Sheila N Prachand; Leo I Gordon
Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines.
Anticancer research 2010;30(4):1131-6.
2009: Andrew M Evens; Lynne I Wagner
Curing Hodgkin's lymphoma: quantity and quality.
The lancet oncology 2009;10(12):1134-5.
2009: Jayesh Mehta; Jayesh Mehta; Olga Frankfurt; Jessica Altman; Andrew M Evens; Martin S Tallman; Leo Gordon; Stephanie Williams; Jane Winter; Jairam Krishnamurthy; Sara Duffey; Veerpal Singh; Richard Meagher; DL Grinblatt; L Kaminer; Seema Singhal
Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation.
Leukemia & lymphoma 2009;50(9):1434-41.
2009: Heather A Lankes; Angela J Fought; Andrew M Evens; Dennis D Weisenburger; Brian Chiu
Vaccination history and risk of non-Hodgkin lymphoma: a population-based, case-control study.
Cancer causes & control : CCC 2009;20(5):517-23.
2009: Jane N Winter; David J Inwards; Stewart Spies; Gregory Wiseman; David Patton; William Erwin; Alfred W Rademaker; Bing Bing Weitner; Stephanie F Williams; Martin S Tallman; Ivana Micallef; Jayesh Mehta; Seema Singhal; Andrew M Evens; Michael Zimmer; Arturo Molina; Christine White; Leo I Gordon
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(10):1653-9.
2009: V Singh; J Krishnamurthy; S Duffey; R Meagher; M Villa; J Monreal; Andrew M Evens; Olga Frankfurt; J Altman; Leo Gordon; Martin S Tallman; S Williams; Jane Winter; Seema Singhal; Jayesh Mehta
Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?
Bone marrow transplantation 2009;43(4):301-5.
2008: Brian Chiu; Bhavana J Dave; Mary H Ward; Angela J Fought; Lifang Hou; Smrati Jain; Susan M Gapstur; Andrew M Evens; Shelia Hoar Zahm; Aaron Blair; Dennis D Weisenburger
Dietary factors and risk of t(14;18)-defined subgroups of non-Hodgkin lymphoma.
Cancer causes & control : CCC 2008;19(8):859-67.
2008: Andrew M Evens; Martin Hutchings; Volker Diehl
Treatment of Hodgkin lymphoma: the past, present, and future.
Nature clinical practice. Oncology 2008;5(9):543-56.
2008: Katalin Kelemen; LoAnn C Peterson; Irene Helenowski; Charles L Goolsby; Borko Jovanovic; Sarah Miyata; Olivia Aranha; Steven T Rosen; Jane N Winter; Beverly P Nelson; Leo I Gordon; Andrew M Evens
CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease.
American journal of clinical pathology 2008;130(2):166-77.
2008: Andrew M Evens; Paul T Schumacker; Irene B Helenowski; Amareshwar T K Singh; Danijela Dokic; Anjeni Keswani; Elizabeth Kordeluk; Adekunle Raji; Jane N Winter; Borko D Jovanovic; Arne Holmgren; Beverly P Nelson; Leo I Gordon
Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family.
British journal of haematology 2008;141(5):676-80.
2008: Andrew M Evens; Jane N Winter; Nanjiang Hou; Beverly P Nelson; Alfred Rademaker; David Patton; Seema Singhal; Olga Frankfurt; Martin S Tallman; Steven T Rosen; Jayesh Mehta; Leo I Gordon
A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma.
British journal of haematology 2008;140(4):385-93.
2007: Lori K Soni; Lifang Hou; Susan M Gapstur; Andrew M Evens; Dennis D Weisenburger; Brian Chiu
Sun exposure and non-Hodgkin lymphoma: a population-based, case-control study.
European journal of cancer (Oxford, England : 1990) 2007;43(16):2388-95.
2007: Kevin A David; Lauren Mauro; Andrew M Evens
Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options.
Current treatment options in oncology 2007;8(5):352-74.
2007: Steven M Trifilio; Seema Singhal; S Williams; Olga Frankfurt; Leo Gordon; Andrew M Evens; Jane Winter; Martin S Tallman; Judy Pi; Jayesh Mehta
Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole.
Bone marrow transplantation 2007;40(5):451-6.
2007: Cara C Tigue; June M McKoy; Andrew M Evens; Steven M Trifilio; Martin S Tallman; Charles L Bennett
Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project.
Bone marrow transplantation 2007;40(3):185-92.
2007: Brian Chiu; Lori Soni; Susan M Gapstur; Angela J Fought; Andrew M Evens; Dennis D Weisenburger
Obesity and risk of non-Hodgkin lymphoma (United States).
Cancer causes & control : CCC 2007;18(6):677-85.
2007: Andrew M Evens; Sheryl L Ziegler; Rohit Gupta; Connie Augustyniak; Leo I Gordon; Jayesh Mehta
Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma.
Clinical lymphoma & myeloma 2007;7(7):472-4.
2007: Andrew M Evens; Jeffrey Cilley; Taylor Ortiz; Mrinal Gounder; Nanjiang Hou; Alfred Rademaker; Sarah Miyata; Kara Catsaros; Connie Augustyniak; Charles L Bennett; Martin S Tallman; Daina Variakojis; Jane N Winter; Leo I Gordon
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.
British journal of haematology 2007;137(6):545-52.
2007: Charles L Bennett; Jonathan R Nebeker; Paul R Yarnold; Cara C Tigue; David A Dorr; June M McKoy; Beatrice J Edwards; John F Hurdle; Dennis P West; Denys Lau ; Cara Angelotta; Sigmund A Weitzman; Steven M. Belknap; Benjamin Djulbegovic; Martin S Tallman; Timothy M Kuzel; Al B Benson; Andrew M Evens; Steven M Trifilio; D Mark Courtney; Dennis W Raisch
Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
Archives of internal medicine 2007;167(10):1041-9.
2007: June M McKoy; Cara Angelotta; Charles L Bennett; Martin S Tallman; Martha Wadleigh; Andrew M Evens; Timothy M Kuzel; Steven M Trifilio; Dennis W Raisch; Jonathan Kell; Daniel J DeAngelo; Francis Giles
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.
Leukemia research 2007;31(5):599-604.
2007: Steven M Trifilio; Gennethel Pennick; Judy Pi; Jennifer Zook; Mary Golf; Kimberley Kaniecki; Seema Singhal; Stephanie Williams; Jane Winter; Martin S Tallman; Leo Gordon; Olga Frankfurt; Andrew M Evens; Jayesh Mehta
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients.
Cancer 2007;109(8):1532-5.
2007: Steven M Trifilio; Charles L Bennett; Paul R Yarnold; June M McKoy; Jorge P Parada; Jayesh Mehta; G Chamilos; Frank J Palella; L Kennedy; K Mullane; Martin S Tallman; Andrew M Evens; Marc H Scheetz; W Blum; D P Kontoyiannis
Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy.
Bone marrow transplantation 2007;39(7):425-9.
2007: Andrew M Evens; J K Altman; Bharat B Mittal; N Hou; A Rademaker; D Patton; L Kaminer; S Williams; S Duffey; Daina Variakojis; S Singhal; Martin S Tallman; J Mehta; Jane N Winter; Leo I Gordon
Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(4):679-88.
2007: Yi-Hua Chen; LoAnn C Peterson; David Dittmann; Andrew M Evens; Steven Rosen; Adela Khoong; T Vincent Shankey; Meryl Forman; Rohit Gupta; Charles L Goolsby
Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia.
American journal of clinical pathology 2007;127(2):182-91.
2006: Charles L Bennett; Cara Angelotta; Paul R Yarnold; Andrew M Evens; Jeffrey A Zonder; Dennis W Raisch; Paul Richardson
Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
JAMA : the journal of the American Medical Association 2006;296(21):2558-60.
2006: Charles L Bennett; Andrew M Evens; Leslie A Andritsos; Lakshmi Balasubramanian; Mark Mai; Matthew J Fisher; Timothy M Kuzel; Cara Angelotta; June M McKoy; Julie M Vose; Philip J Bierman; David J Kuter; Steven M Trifilio; Steven M Devine; Martin S Tallman
Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.
British journal of haematology 2006;135(5):642-50.
2006: Jayesh Mehta; Leo I Gordon; Martin S Tallman; Jane N Winter; Andrew M Evens; A O Evens; O Frankfurt; SF Williams; DL Grinblatt; L Kaminer; R Meagher; Seema Singhal
Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?
Bone marrow transplantation 2006;38(2):95-100.
2006: Lakshmi Balasubramanian; Andrew M Evens
Targeting angiogenesis for the treatment of sarcoma.
Current opinion in oncology 2006;18(4):354-9.
2006: Steven M Trifilio; Leo Gordon; Seema Singhal; Martin S Tallman; Andrew M Evens; K Rashid; M Fishman; K Masino; Judy Pi; Jayesh Mehta
Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.
Bone marrow transplantation 2006;37(11):997-1001.
2006: Seema Singhal; Leo I Gordon; Martin S Tallman; Jane N Winter; Andrew M Evens; A O Evens; O Frankfurt; SF Williams; DL Grinblatt; L Kaminer; R Meagher; Jayesh Mehta
Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation.
Bone marrow transplantation 2006;37(6):553-7.
2006: Mujahid A Rizvi; Andrew M Evens; Martin S Tallman; Beverly P Nelson; Steven T Rosen
T-cell non-Hodgkin lymphoma.
Blood 2006;107(4):1255-64.
2006: Andrew M Evens; Christiane Querfeld; Steven T Rosen
T-cell non-Hogdkin's lymphoma.
Cancer treatment and research 2006;131():161-220.
2006: Ryan H Engel; Andrew M Evens
Oxidative stress and apoptosis: a new treatment paradigm in cancer.
Frontiers in bioscience : a journal and virtual library 2006;11():300-12.
2005: Charles L Bennett; Denis Cournoyer; Kenneth R Carson; Jérôme Rossert; stefano luminari; Andrew M Evens; Francesco Locatelli; Steven M. Belknap; June M McKoy; E Allison Lyons; Benjamin Kim; Rishi Sharma; Stacey Costello; Edwin B Toffelmire; George A Wells; Hans A Messner; Paul R Yarnold; Steven M Trifilio; Dennis W Raisch; Timothy M Kuzel; Allen R Nissenson; Lay-Cheng Lim; Martin S Tallman; Nicole Casadevall
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.
Blood 2005;106(10):3343-7.
2005: M Tomblyn; Leo I Gordon; Seema Singhal; Martin S Tallman; S Williams; Jane N Winter; Andrew M Evens; Jayesh Mehta
Use of total leukocyte and platelet counts to guide stem cell apheresis in healthy allogeneic donors treated with G-CSF.
Bone marrow transplantation 2005;36(8):663-6.
2005: Andrew M Evens; Lakshmi Balasubramanian; Leo I Gordon
Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies.
Current treatment options in oncology 2005;6(4):289-96.
2005: Charles L Bennett; Jonathan R Nebeker; E Allison Lyons; Matthew H Samore; Marc D Feldman; June M McKoy; Kenneth R Carson; Steven M. Belknap; Steven M Trifilio; Glen T Schumock; Paul R Yarnold; Charles J Davidson; Andrew M Evens; Timothy M Kuzel; Jorge P Parada; Denis Cournoyer; Dennis P West; Oliver Sartor; Martin S Tallman; Dennis W Raisch
The Research on Adverse Drug Events and Reports (RADAR) project.
JAMA : the journal of the American Medical Association 2005;293(17):2131-40.
2005: A Gidron; Amit Verma; M Doyle; L Boggio; Andrew M Evens; Leo Gordon; Seema Singhal; Martin S Tallman; S Williams; Jane Winter; Jayesh Mehta
Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?
Bone marrow transplantation 2005;35(3):243-6.
2005: Andrew M Evens; Philip Lecane; Darren Magda; Sheila Prachand; Seema Singhal; Jeff Nelson; Richard A Miller; Ronald B Gartenhaus; Leo I Gordon
Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells.
Blood 2005;105(3):1265-73.
2005: Andrew M Evens; Charles L Bennett; stefano luminari
Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group.
Best practice & research. Clinical haematology 2005;18(3):481-9.
2005: Kenneth R Carson; Andrew M Evens; Charles L Bennett; stefano luminari
Clinical characteristics of erythropoietin-associated pure red cell aplasia.
Best practice & research. Clinical haematology 2005;18(3):467-72.
2004: Andrew M Evens
Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer.
Current opinion in oncology 2004;16(6):576-80.
2004: Andrew M Evens; Leo I Gordon
Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond.
Clinical lymphoma 2004;5 Suppl 1():S11-5.
2004: Andrew M Evens; J Mehta; Leo I Gordon
Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress.
Bone marrow transplantation 2004;34(7):561-71.
2004: Charles L Bennett; stefano luminari; Allen R Nissenson; Martin S Tallman; Stephen A Klinge; Norene McWilliams; June M McKoy; Benjamin Kim; E Allison Lyons; Steven M Trifilio; Dennis W Raisch; Andrew M Evens; Timothy M Kuzel; Glen T Schumock; Steven M. Belknap; Francesco Locatelli; Jérôme Rossert; Nicole Casadevall
Pure red-cell aplasia and epoetin therapy.
The New England journal of medicine 2004;351(14):1403-8.
2004: Andrew M Evens; Martin S Tallman; Ronald B Gartenhaus
The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future.
Leukemia research 2004;28(9):891-900.
2004: Andrew M Evens; Ronald B Gartenhaus
Treatment of T-cell non-Hodgkin's lymphoma.
Current treatment options in oncology 2004;5(4):289-303.
2004: Andrew M Evens; Sheila Prachand; Bo Shi; Mary Paniaqua; Leo I Gordon; Ronald B Gartenhaus
Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(4):1481-91.
2003: Bo Shi; Hsin-Ling Hsu; Andrew M Evens; Leo I Gordon; Ronald B Gartenhaus
Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies.
Blood 2003;102(1):297-302.
2003: Andrew M Evens; Ronald B Gartenhaus
Molecular etiology of mature T-cell non-Hodgkin's lymphomas.
Frontiers in bioscience : a journal and virtual library 2003;8():d156-75.
2002: Andrew M Evens; Hau C Kwaan; Dixon B Kaufman; Charles L Bennett
TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology.
Transplantation 2002;74(6):885-7.
2002: Andrew M Evens; Leo I Gordon
Burkitt's and Burkitt-like lymphoma.
Current treatment options in oncology 2002;3(4):291-305.